410 Medical completes $14M Series B financing

This article originally appeared via NCBiotech's blog

410 Medical, Inc., a medical device company focused on innovative technologies for emergency and critical care, has completed a $14 million Series B financing. Existing investor Hatteras Venture Partners led the funding round with participation from Orlando Health Ventures, Ballad Ventures, OSF Healthcare, WakeMed, Rex Health Ventures, CU Healthcare Innovations Fund, and Sarnova.

“We are thrilled to add Rex Health Ventures, CU Healthcare Innovations, and Sarnova to our 410 Medical investor syndicate,” said Kyle Chenet, Chief Executive Officer at 410 Medical. “This funding accelerates our ability to expand access to LifeFlow, ensuring that critically ill patients receive timely and effective resuscitation. To date, clinicians have used LifeFlow to treat over 50,000 patients across the country in a wide variety of care settings. Patient outcomes and user feedback have been outstanding. The growing clinical adoption and positive provider feedback reinforce the need for effective resuscitation tools.”

Urgent needs in trauma, emergency care

Severe hemorrhage remains a leading cause of preventable death in the US. At the same time, sepsis affects more than one million patients annually and is the most expensive condition treated in US hospitals. Due to the limitations of traditional infusion methods, many patients with these life-threatening conditions do not receive timely resuscitation with blood or IV fluid. LifeFlow is designed to help medical providers deliver fluid and blood efficiently and effectively in any environment, improving patient outcomes when minutes matter and delays in resuscitation can lead to organ failure or death.

Hospitals and EMS teams across the US are increasingly adopting LifeFlow as part of advanced resuscitative care programs that improve outcomes for patients with hemorrhagic shock, sepsis, and other life-threatening conditions.

“We are excited about the implementation of LifeFlow at UNC Rex as we continue to advance protocols that help our emergency clinicians deliver effective resuscitation for septic shock, trauma and other time-sensitive conditions,” said Charul Haugan, MD, Medical Director of Clinical Optimization at UNC Health.

Co-founded by WakeMed physician

Founded in 2013, 410 Medical is an RTP-based medical device company focused on advanced resuscitation technologies to improve the care of critically ill patients. Its lead product LifeFlow® received FDA clearance in 2016 and is used to enhance the administration of fluid and blood products for patients with sepsis, hemorrhagic shock, and other life-threatening conditions.

Since its launch, LifeFlow has been used in over 50,000 patients. The device has been adopted by leading hospitals, EMS agencies, and military medical units across the U.S., helping clinicians rapidly administer blood and fluids in high-stakes situations. With its ability to deliver 500 mL of fluid or a unit of blood in just two minutes, LifeFlow has demonstrated its potential to improve patient outcomes by enabling faster, more efficient resuscitation compared to traditional methods.

410 Medical was co-founded by Mark Piehl, a physician at WakeMed Health & Hospitals in Raleigh, in 2013 to develop innovative products to help emergency clinicians provide better care for critically ill patients. Piehl, who is 410’s chief medical officer, is a pediatric intensivist at WakeMed, where he was medical director of WakeMed Children’s Hospital from 2009 to 2015.

The North Carolina Biotechnology Center has partnered with 410 Medical since 2016 when they first discussed a Small Business Research Loan.

In 2023 the company raised $7.5 million, in the first phase of a Series B financing led by Durham-based Hatteras Venture Partners with participation from existing investors including Orlando Health Ventures, OSF Healthcare and Raleigh-based WakeMed, and new investors Ballad Ventures and Catalyst by Wellstar.

410 Medical takes its name in part from the calculation of fluid-delivery goals in pediatric septic shock (four boluses every 10 minutes = 410).